Connect with us

News

Merck's experimental COVID-19 pill under review by Health Canada – CTV News

Published

 on


TORONTO —
Health Canada says it is working with international counterparts to review an experimental pill from drugmaker Merck, which the company reports can reduce hospitalizations and deaths by half in patients sick with COVID-19.

During a news briefing Friday, the Public Health Agency of Canada (PHAC) said Merck first submitted an approval request for molnupiravir, a twice-daily oral antiviral agent taken within five days after the onset of symptoms, as a potential treatment for COVID-19 on Aug. 13.

According to PHAC, the submission was accepted under the Minister of Health’s Interim Order, which allows for the review of “early safety, quality and efficacy data” while later-stage clinical trials take place

Canada’s chief medical adviser Dr. Supriya Sharma said review of the treatment is ongoing as more data from trials becomes available. Sharma said Health Canada will make an approval decision only when all necessary evidence has been submitted and reviewed.

“We are looking at it. We’re going through … the data,” she said.

Sharma said Health Canada has no specific time for completion of the review as it can take “months,” but also that the pill will be evaluated and “held to the standards” as any other medication or treatment.

According to Health Canada, it only authorizes treatments, including those for COVID-19, following a “thorough scientific review of the safety, efficacy and quality data.”

“A treatment must show evidence that it works well, is of high quality and is safe. The available data must demonstrate that the treatment’s benefits outweigh its risks,” the agency said in a statement.

Canada currently has four approved treatments for COVID-19, including Canadian-made COVID-19 monoclonal antibody bamlanivimab and antiviral medication remdesivir. However, these treatments require an IV or injection.

If cleared, molnupiravir would be the first oral pill shown to treat COVID-19.

Merck and its partner Ridgeback Biotherapeutics announced Friday that early results from its trials show that patients who received molnupiravir within five days of COVID-19 symptoms had about half the rate of hospitalization and death as those who received a placebo.

The study tracked 775 adults with mild-to-moderate COVID-19 who were considered to be at higher risk for severe disease because of health problems such as obesity, diabetes or heart disease. Among patients taking molnupiravir, 7.3 per cent were either hospitalized or died at the end of 30 days, compared with 14.1 per cent of those who recieved the placebo.

The results were so strong that an independent group of medical experts monitoring the trial recommended stopping it early.

“It really takes what is the devastating disease and hopefully gives people confidence that it can be manageable,” Merck CEO Robert Davis said in an interview with CTV News.

Davis called the pill a “game-changer” that could potentially be used to treat non-hospitalized, less severe cases of COVID-19 from home.

Earlier study results from Merck showed the drug did not benefit patients who were already hospitalized with severe disease. Experts say this is expected, given that antiviral drugs are most effective before the virus ramps up in the body.

The study results have not been reviewed by outside experts, which is the usual procedure for vetting new medical research.

Merck said it plans to submit the data in the coming days to health officials in the U.S. and other countries to authorize the pill’s use.

A decision from the U.S. Food and Drug Administration could come within weeks after that, and be distributed soon after.

Similar to other antivirals, molnupiravir works by interfering with the virus’s ability to copy its genetic code and reproduce itself, a process known as excessive mutagenesis or “error catastrophe.”

Virologists out of the University of Alberta (U of A) tested the compound to see its mechanism of action, independently of Merck. Their findings were published in May in the Journal of Biological Chemistry.

Matthias Gotte, a professor of medical microbiology and immunology at the U of A, led the research and said in an interview with CTV News that the drug attacks the virus, but doesn’t block or inhibit its replication.

Gotte said molnupiravir changes the viral genome, causing the replication engine of the virus to make “sloppy copies” of these altered genomes that are useless and not viable.

While Merck only studied its drug in people who were not vaccinated, Gotte said it may also potentially work in vaccinated patients who get less severe, breakthrough COVID-19 infections.

However, Gotte said it is important to note that molnupiravir is not a replacement for vaccines.

“The principles are completely different. Vaccines, they prevent severe disease, and the drugs are used to treat,” he said. “Once you are infected, the big problem is with these antiviral drugs you can’t use them late, you have to use them as early as possible.”

Eleanor Fish, a senior immunologist with the Toronto-based University Health Network who is not affiliated with the U of A study or Merck, says the approval of molnupiravir would help those who are ineligible for vaccination as well as those most at risk of severe disease.

“We can jump up and down in the U.S. and Canada and say, ‘Hey, we’ve got another tool in our armoury,’ [and] that’s going to be great,” Fish told CTV News.

She added that the drug’s approval in other parts of the world will help countries that are struggling to acquire COVID-19 vaccines.

“I see this more as [an] incredible opportunity, with a limited number of vaccines available globally, to send this out to those jurisdictions where vaccination rates are very, very low,” she said.

With files from The Associated Press

Adblock test (Why?)



Source link

Continue Reading

Health

Former U.S. President Clinton leaves hospital, will return to New York

Published

 on

Former U.S. President Bill Clinton walked out of a Southern California hospital on Sunday after being admitted last week for a Urological Infection, live video showed.

Clinton, 75, will return to New York and remain on antibiotics, Dr. Alpesh Amin, who had been overseeing his care at the hospital, said in a statement released by Clinton’s spokesman. His fever and white blood cell count have normalized, Amin added.

The former president had been in California for an event for his foundation and was treated at the University of California Irvine Medical Center’s intensive care unit after suffering from fatigue and being admitted on Tuesday.

He left the medical center accompanied by his wife, former Secretary of State and 2016 Democratic presidential nominee Hillary Clinton.

The two-term president, who has had previous heart problems, held the White House from 1993 to 2001.

(Reporting by Susan Heavey, Editing by Nick Zieminski)

Continue Reading

News

China condemns U.S., Canada for sending warships through Taiwan Strait

Published

 on

The  Chinese military on Sunday condemned the United States and Canada for each sending a warship through the Taiwan Strait last week, saying they were threatening peace and stability in the region.

China claims democratically-ruled Taiwan as its own territory, and has mounted repeated air force missions into Taiwan’s air defence identification zone (ADIZ) over the past year, provoking anger in Taipei.

China sent around 150 aircraft into the zone over a four-day period beginning on Oct. 1 in a further heightening of tension between Beijing and Taipei that has sparked concern internationally.

The U.S. military said the Arleigh Burke-class guided missile destroyer USS Dewey sailed through the narrow waterway that separates Taiwan from its giant neighbour China along with the Canadian frigate HMCS Winnipeg on Thursday and Friday.

“Dewey’s and Winnipeg’s transit through the Taiwan Strait demonstrates the commitment of the United States and our allies and partners to a free and open Indo-Pacific,” it added.

China’s People’s Liberation Army’s Eastern Theatre Command said its forces monitored the ships and “stood guard” throughout their passage.

“The United States and Canada colluded to provoke and stir up trouble… seriously jeopardising peace and stability of the Taiwan Strait,” it said.

“Taiwan is part of Chinese territory. Theatre forces always maintain a high level of alert and resolutely counter all threats and provocations.”

U.S. Navy Ships have been transiting the strait roughly monthly, to the anger of Beijing, which has accused Washington of stoking regional tensions. U.S. allies occasionally also send ships through the strait, including Britain https://www.reuters.com/world/asia-pacific/british-frigate-sails-through-taiwan-strait-2021-09-27last month.

While tensions across the Taiwan Strait have risen, there has been no shooting and Chinese aircraft have not entered Taiwanese air space, concentrating their activity in the southwestern part of the ADIZ.

While including Taiwanese territorial air space, the ADIZ encompasses a broader area that Taiwan monitors and patrols that acts to give it more time to respond to any threats.

Taiwan’s defence ministry said on Sunday that three Chinese aircraft – two J-16 fighters and an anti-submarine aircraft – flew into the ADIZ again.

(Reporting by Ryan Woo in Beijing, Ben Blanchard in Taipei and Idrees Ali in Washington; Editing by Pravin Char and John

Continue Reading

News

No end in sight to volcanic eruption on Spain’s La Palma – Canaries president

Published

 on

There’s no immediate end in sight to the  volcanic eruption that has caused chaos on the Spanish isle of La Palma since it began about a month ago, the president of the Canary Islands said on Sunday.

There were 42 seismic movements on the island on Sunday, the largest of which measured 4.3, according to the Spanish National Geographical Institute.

“There are no signs that an end of the eruption is imminent even though this is the greatest desire of everyone,” President Angel Víctor Torres said at a Socialist party conference in Valencia, citing the view of scientists.

Streams of lava have laid waste to more than 742 hectares (1833 acres) of land and destroyed almost 2,000 buildings on La Palma since the volcano started erupting on Sept. 19.

About 7,000 people have been evacuated from their homes on the island, which has about 83,000 inhabitants and forms part of the Canary Islands archipelago off northwestern Africa.

Airline Binter said it had cancelled all its flights to La Palma on Sunday because of ash from the volcano.

“Due to the current situation of the ash cloud, operations with La Palma will continue to be paralyzed throughout today. We continue to evaluate the situation,” the airline tweeted.

Almost half – 22 out of 38 – of all flights to the island on Sunday have been cancelled, state airport operator Aena said, but the airport there remains open.

(Reporting by Graham Keeley; Editing by Pravin Char)

Continue Reading

Trending